Insvada is an oral new generation short-acting hypoglycemic medication that rapidly lowers blood glucose levels, stimulating the release of insulin by the pancreas; the medication effect depends in the number of functioning β-cells, preserved in the pancreatic islets. Repaglinide blocks ATP-sensitive potassium channels in the membranes of functionally active pancreatic islet apparatus β-cells, induces their depolarization and сalcium channel opening, evoking the release of insulin. An insulinotropic response is observed within 30 minutes after the administration and is accompanied by blood glucose level lowering in the period of food intake (insulin concentration doesn’t increase between meals).
Insvada
Repaglinide 0.5mg Tablets №30
Insvada
Repaglinide 1mg Tablets №30
Insvada
Repaglinide 2mg Tablets №30